Form 4: GoodRx Major Shareholder Spectrum Equity Converts and Distributes Millions of Shares, Sells Portion

Spectrum Equity, a significant shareholder in GoodRx Holdings, Inc., has reported the conversion of millions of Class B shares to Class A, followed by a large pro rata distribution to its partners and the sale of a portion of these shares.

Summary

• Spectrum Equity VII, L.P., Spectrum VII Investment Managers' Fund, L.P., and Spectrum VII Co-Investment Fund L.P. converted a total of 3,999,999 shares of GoodRx Class B Common Stock into Class A Common Stock on a one-for-one basis on June 5, 2025.
• On June 5, 2025, Spectrum Equity VII, L.P. made a pro rata distribution of 3,989,323 Class A shares to its general and limited partners for no consideration.
• On June 6, 2025, Spectrum VII Investment Managers' Fund, L.P. sold 6,828 Class A shares and Spectrum VII Co-Investment Fund L.P. sold 3,849 Class A shares.
• The sales were executed at a weighted average price of $4.0935 per share, with prices ranging from $4.08 to $4.11 per share.
• Following these transactions, Spectrum Equity VII, L.P. indirectly beneficially owns 18,854,669 Class B shares (convertible to Class A), Spectrum VII Investment Managers' Fund, L.P. indirectly owns 32,273 Class B shares, and Spectrum VII Co-Investment Fund L.P. indirectly owns 18,191 Class B shares.
• The transactions were made pursuant to a Rule 10b5-1 pre-arranged trading plan.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the significant reduction in insider ownership through both distribution and direct sales, even though the transactions are pre-planned under a 10b5-1 plan. This indicates a partial exit strategy by a major investor.

Negatives

• Significant reduction in direct beneficial ownership by Spectrum Equity VII, L.P. through a large pro rata distribution of shares.
• Sale of Class A shares by Spectrum VII Investment Managers' Fund, L.P. and Spectrum VII Co-Investment Fund L.P. at a weighted average price of $4.0935, indicating a partial divestment by these entities.

Risks

• The distribution of a large block of shares to partners could lead to increased selling pressure on GoodRx's Class A common stock if recipients decide to liquidate their holdings.
• The sales by affiliated funds represent a reduction in insider ownership, which may be perceived negatively by the market.

Future Outlook

This Form 4 filing does not provide any forward-looking statements or guidance regarding GoodRx's future operations or financial performance.

Industry Context

This filing reflects a change in ownership by a major institutional investor, Spectrum Equity, which is common for private equity funds as they manage their portfolio companies through various stages. It does not directly comment on broader industry trends in the digital health or pharmaceutical discount sectors.

Related Party Transactions

• Spectrum Equity VII, L.P. made a pro rata distribution of 3,989,323 shares of Class A Common Stock to its general partner and limited partners for no consideration. This is a transaction between the fund and its related investors.

Stakeholder Impact

• Shareholders: Potential for increased supply of Class A shares in the market, which could exert downward pressure on the stock price.
• Investors: May interpret the reduction in ownership by a major institutional investor as a negative signal, potentially impacting investment decisions.

Next Steps

• The Reporting Persons undertake to provide full information regarding the number of shares sold at each separate price within the reported range upon request from the Issuer, any security holder, or the SEC staff.

Key Dates

Recommendation

Keywords

GoodRx, GDRX, SEC Form 4, insider trading, beneficial ownership, stock conversion, stock distribution, stock sale, Spectrum Equity, 10b5-1 plan